DOCSLIB.ORG

Progress and Prospects: Genetic Engineering in Xenotransplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progress and Prospects: Genetic Engineering in Xenotransplantation Gene Therapy (2008) 15, 1247–1256 & 2008 Macmillan Publishers Limited All rights reserved 0969-7128/08 $32.00 www.nature.com/gt REVIEW Progress and prospects: genetic engineering in xenotransplantation S Le Bas-Bernardet1, I Anegon1 and G Blancho1,2 1INSERM, U643, Nantes, France; CHU Nantes, Institut de Transplantation et de Recherche en Transplantation, ITERT, Nantes, France; Universite´ de Nantes, Faculte´ de Me´decine, Nantes, France and 2Service de Ne´phrologie, Immunologie Clinique et Transplantation, CHU Nantes, Nantes, France In this review, we summarize the work published over the last the knockout of the a1,3-galactosyltransferase gene, fol- 2 years using genetic modifications of animals in the field of lowed by genetic engineering aimed at reducing the humoral xenotransplantation. Genetic engineering of the donor has and cellular immune response, complement activation and become a powerful tool in xenotransplantation, both for the coagulation. Finally, we report on the genetic modification of inactivation of one particular porcine gene and for the pigs to reduce porcine endogenous retrovirus infection risk addition of human genes with the goal of overcoming in the xenogeneic context. xenogeneic barriers. We summarize the work relative to Gene Therapy (2008) 15, 1247–1256; doi:10.1038/gt.2008.119 Keywords: aGal; knockout; xenoantibodies; transgenes; complement; xenotransplantation In brief Progress Prospects Genetic engineering approaches leading to a reduc- Deletion of the iGb3S gene in addition to deletion of tion of aGal expression in donor cells/organs and GalT in donor cells/organs. production of a1,3-galactosyltransferase knockout Crossbreeding of GalT-KO pigs with pigs transgenic (GalT-KO) pigs. for EndoGalC. Control of complement through the use of transgenic Crossbreeding of GalT-KO pigs with pigs transgenic pigs for multiple complement regulatory proteins. for different human anticoagulant and/or comple- Genetic engineering for molecules that control coa- ment regulatory proteins to decrease humoral and gulation activation. cellular immunological barriers. Genetic engineering for molecules that modify the Use of pig pancreatic islets genetically modified to cellular xenogeneic immune response express transgenes that control the cellular xeno- Control of PERV expression in pig cells/organs by geneic immune response and coagulation. RNA interference. Controlling PERV expression in pig cells/organs used in xenotransplantation to reduce the risk of host infection. virus transmission to humans. Now, pigs are considered for the future as animals of choice (porcine valves Introduction used for years in humans, may not be considered as xenotransplantation as the tissue is devitalized before Transplantation is currently facing a problem of organ implantation). In fact, pigs have been identified as shortage; waiting lists are increasing with some of these potential donors, primarily because of their physiology patients dying before any proposition of an organ transplant. One solution could be to increase the donor and anatomy being similar to humans. Moreover, there ‘reservoir’ by using animal organs: that is, xenotrans- are no major ethical considerations regarding their use in plantation. In the past, non-human primates (NHPs) medicine. Finally, their potential has been increased by were used as organ donors for humans (1960–1992), but the application of the most recent techniques of genetic are no longer considered as potential donors essentially manipulation: transgenesis, gene transfer through viral for ethical reasons and for a high risk of endogenous vector and cloning through nuclear transfer. However, some significant problems remain regarding their use: immunological barriers and the risk of viral trans- Correspondence: Dr G Blancho, Nephrology Unit, INSERM U643- mission. Manipulations of the pig genome targeting the ITERT, CHU Hoˆtel Dieu, 30 boulevard Jean Monnet, 44093 Nantes, Cedex 1, France. human or NHP immune responses, coagulation dis- E-mail: [email protected] orders and viral risk are research approaches that will be Received 13 May 2008; revised 30 June 2008; accepted 1 July 2008 addressed in this review (Table 1). Gene Therapy 1248 Table 1 Progress in xenotransplantation through genetic engineering approaches Technique Molecule Models Study results References Donor/target cells Recipient/responder cells Genetic engineering approaches leading to a reduction of aGal expression in donor cells/organs and production of a1,3-galactosyltransferase knockout (GalT-KO) pigs Gene transfer EndoGalC EndoGalC transgenic mice Mice transgenic for EndoGalC present Watanabe et al.1 reduced aGal expression, but an abnormal phenotype Cloning, GnT-I Transfected pig cells with Human serum Transfection with a pigGnT-I(320) mutation Matsunami et al.2 direct mutagenesis pigGnT-I mutations reduced the antigenicity to human sera Gene inactivation, GalT iGb3 vs GalT-transfected GalT-KO mice aGal synthesized by iGb3S is as Milland et al.3 gene transfer iGb3S 293 cells immunogenic as GalT Genetic engineering in xenotransplantation Gene inactivation GalT GalT-KO pig Complementarity breeding and SCNT in Nottle et al.4 GalT-KO pig production Gene inactivation GalT GalT-KO pig heart Baboon No improvement in coagulation problems Ezzelarab et al.5 in the GalT-KO context 6 Gene inactivation GalT PBMC from WT vs GalT-KO Healthy human vs Allosensitized compared to unsensitized Hara et al. S Le Bas-Bernardet pig patients awaiting renal patients at no greater risk of humoral transplantation rejection to pig xenografts Control of complement through the use of transgenic pigs for multiple complement regulatory proteins 7 DNA sequencing, hDAF hDAF transgenic pig heart Cynomolgus A restricted family IgVH3 gene encoded for Zahorsky-Reeves et al. gene transfer, their XNA et al phagemid vector Gene transfer hCD59 hCD59 transgenic Pig Microinjection of one hCD59 transgene into Deppenmeier et al.8 zygote pronuclei is a suitable technique to generate hCD59 transgenic pigs Gene transfer hCD55 Ex vivo perfused hCD55/59 Fresh human blood Xenotransplantation of lungs from hCD55 Poling et al.9 hCD59 transgenic porcine lung and hCD59 transgenic pigs induced, respectively, a partial protection and no effect on pulmonary dysfunction compared to nontransgenic lungs Gene transfer hDAF Pig heart Baboon Deregulated coagulation correlated closely Wu et al.10 hMCP with and probably causes primary failure of pig hearts transgenic for hCRP Gene transfer, hDAF Pig fibroblasts Human and baboon Much higher expression of hDAF might be Liu et al.11 plasmid sera beneficial in protecting pig organs from one humoral response SMGT hDAF Ex vivo perfused hDAF Fresh human blood Hearts from hDAF transgenic pigs Smolenski et al.12 transgenic porcine heart generated by SMGT are protected from HAR after contact with human blood Gene transfer, sCR1 Cultured human sCR1 Human AB serum Transgenic pECs expressing human sCR1 Manzi et al.13 plasmid transgenic porcine ECs are resistant to in vitro lysis by human serum Cloning, ICAM-2 Simian Virus 40-transformed The P8 sites associated with enhancer Godwin et al.14 gene transfer, promoter pig aortic endothelial cells activity contained in pig ICAM-2 pGL3-basic, (SVAP), COS-1 promoters seem to be crucial for achieving gene transfer, strong endothelial-specific transgene pRL-TK expression Table 1 Continued Technique Molecule Models Study results References Donor/target cells Recipient/responder cells Genetic engineering for molecules that control coagulation activation Gene transfer hCD39 In vitro islets isolated from Human blood Expression of transgenic hCD39 on Dwyer et al.15 hCD39 transgenic mice murine islets inhibits the in vitro clotting of human blood Genetic engineering for molecules that modify the cellular xenogeneic immune response Gene transfer, GalT (1) Autologous GalT-KO mice (1) Immunization of Transduction with lentiviral vectors results Mitsuhashi et al.16 lentiviral vector BM cells transfected with GalT-reconstituted in chimerism at sufficient levels to inhibit GalT mice (by BMT) with anti-aGal Ab production and to induce (2) Rabbit RBC rabbit RBC long-term tolerance under (2) GalT-BMT mice nonmyeloablative conditions transplanted with aGal mice hearts Gene transfer, GalT (1) Autologous Rhesus BM Immunization of Gene therapy achieves low-level, Fischer-Lougheed et al.17 lentiviral vector cells transfected with GalT aGalT+BM Rhesus long-term aGal chimerism sufficient to (2) Pig fibroblasts macaques with inhibit production of anti-aGal Ab after porcine cells immunization with porcine cells in rhesus macaques Gene transfer, CTLA4-Ig WT vs CTLA4-Ig-transduced Splenocytes from mice Production of CTLA4-Ig inhibits primed Mulley et al.18 lentiviral vector PIEC primed with PIEC indirect T-cell proliferation and cytokine responses in vitro S Le Bas-Bernardet Genetic engineering in xenotransplantation Cloning, PD-L1 Porcine PD-L1-transfected Human CD4+ T cells Porcine PD-L1 inhibited human activated Jeon et al.19 gene transfer CHO CD4+ T-cell proliferation inducing activated T-cell apoptosis Gene transfer HLA-E SCT PECs Human NK cells Transgenic expression of HLA-E SNCT Lilienfeld et al.20 induced a significant decrease of et al polyclonal human NK-mediated cytotoxicity against pEC but did not affect NK cell adhesion to pEC Control of PERV expression in pig cells/organs by RNA interference Gene transfer, PERV siRNA Pol2 transgenic Inhibition of PERV expression in Dieckhoff et al.21 lentiviral vector porcine cells
Load more

Recommended publications
  • Genetic Susceptibility to Chronic Wasting Disease in Free-Ranging White-Tailed Deer: Complement Component C1q and Prnp Polymorphisms Julie A
    Natural Resource Ecology and Management Natural Resource Ecology and Management Publications 12-2009 Genetic susceptibility to chronic wasting disease in free-ranging white-tailed deer: Complement component C1q and Prnp polymorphisms Julie A. Blanchong Iowa State University, [email protected] Dennis M. Heisey United States Geological Survey Kim T. Scribner Michigan State University Scot V. Libants Michigan State University Chad Johnson UFonilvloerwsit ythi of sW aiscondn asiddn - itMionadisoaln works at: http://lib.dr.iastate.edu/nrem_pubs Part of the Animal Diseases Commons, Genetics Commons, Natural Resources Management See next page for additional authors and Policy Commons, Veterinary Infectious Diseases Commons, and the Zoology Commons The ompc lete bibliographic information for this item can be found at http://lib.dr.iastate.edu/ nrem_pubs/84. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Natural Resource Ecology and Management at Iowa State University Digital Repository. It has been accepted for inclusion in Natural Resource Ecology and Management Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Genetic susceptibility to chronic wasting disease in free-ranging white- tailed deer: Complement component C1q and Prnp polymorphisms Abstract The eg netic basis of susceptibility to chronic wasting disease (CWD) in free-ranging cervids is of great interest. Association studies of disease susceptibility in free-ranging populations, however, face considerable challenges including: the need for large sample sizes when disease is rare, animals of unknown pedigree create a risk of spurious results due to population admixture, and the inability to control disease exposure or dose.
    [Show full text]
  • Neutrophil Chemoattractant Receptors in Health and Disease: Double-Edged Swords
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE Neutrophil chemoattractant receptors in health and disease: double-edged swords Mieke Metzemaekers1, Mieke Gouwy1 and Paul Proost 1 Neutrophils are frontline cells of the innate immune system. These effector leukocytes are equipped with intriguing antimicrobial machinery and consequently display high cytotoxic potential. Accurate neutrophil recruitment is essential to combat microbes and to restore homeostasis, for inflammation modulation and resolution, wound healing and tissue repair. After fulfilling the appropriate effector functions, however, dampening neutrophil activation and infiltration is crucial to prevent damage to the host. In humans, chemoattractant molecules can be categorized into four biochemical families, i.e., chemotactic lipids, formyl peptides, complement anaphylatoxins and chemokines. They are critically involved in the tight regulation of neutrophil bone marrow storage and egress and in spatial and temporal neutrophil trafficking between organs. Chemoattractants function by activating dedicated heptahelical G protein-coupled receptors (GPCRs). In addition, emerging evidence suggests an important role for atypical chemoattractant receptors (ACKRs) that do not couple to G proteins in fine-tuning neutrophil migratory and functional responses. The expression levels of chemoattractant receptors are dependent on the level of neutrophil maturation and state of activation, with a pivotal modulatory role for the (inflammatory) environment. Here, we provide an overview
    [Show full text]
  • An Anticomplement Agent That Homes to the Damaged Brain and Promotes Recovery After Traumatic Brain Injury in Mice
    An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice Marieta M. Rusevaa,1,2, Valeria Ramagliab,1, B. Paul Morgana, and Claire L. Harrisa,3 aInstitute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; and bDepartment of Genome Analysis, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands Edited by Douglas T. Fearon, Cornell University, Cambridge, United Kingdom, and approved September 29, 2015 (received for review July 15, 2015) Activation of complement is a key determinant of neuropathology to rapidly and specifically inhibit MAC at sites of complement and disability after traumatic brain injury (TBI), and inhibition is activation, and test its therapeutic potential in experimental TBI. neuroprotective. However, systemic complement is essential to The construct, termed CD59-2a-CRIg, comprises CD59a linked fight infections, a critical complication of TBI. We describe a to CRIg via the murine IgG2a hinge. CD59a prevents assembly targeted complement inhibitor, comprising complement receptor of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b of the Ig superfamily (CRIg) fused with complement regulator CD59a, deposited at sites of complement activation (17). The IgG2a designed to inhibit membrane attack complex (MAC) assembly at hinge promotes dimerization to increase ligand avidity. CD59- sites of C3b/iC3b deposition. CRIg and CD59a were linked via the 2a-CRIg protected in the TBI model, demonstrating that site- IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b targeted anti-MAC therapeutics may be effective in prevention binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited of secondary neuropathology and improve neurologic recovery MAC formation and prevented complement-mediated lysis in vitro.
    [Show full text]
  • In Vitro Selection for Adhesion of Plasmodium Falciparum-Infected Erythrocytes to ABO Antigens Does Not Affect Pfemp1 and RIFIN
    www.nature.com/scientificreports OPEN In vitro selection for adhesion of Plasmodium falciparum‑infected erythrocytes to ABO antigens does not afect PfEMP1 and RIFIN expression William van der Puije1,2, Christian W. Wang 4, Srinidhi Sudharson 2, Casper Hempel 2, Rebecca W. Olsen 4, Nanna Dalgaard 4, Michael F. Ofori 1, Lars Hviid 3,4, Jørgen A. L. Kurtzhals 2,4 & Trine Staalsoe 2,4* Plasmodium falciparum causes the most severe form of malaria in humans. The adhesion of the infected erythrocytes (IEs) to endothelial receptors (sequestration) and to uninfected erythrocytes (rosetting) are considered major elements in the pathogenesis of the disease. Both sequestration and rosetting appear to involve particular members of several IE variant surface antigens (VSAs) as ligands, interacting with multiple vascular host receptors, including the ABO blood group antigens. In this study, we subjected genetically distinct P. falciparum parasites to in vitro selection for increased IE adhesion to ABO antigens in the absence of potentially confounding receptors. The selection resulted in IEs that adhered stronger to pure ABO antigens, to erythrocytes, and to various human cell lines than their unselected counterparts. However, selection did not result in marked qualitative changes in transcript levels of the genes encoding the best-described VSA families, PfEMP1 and RIFIN. Rather, overall transcription of both gene families tended to decline following selection. Furthermore, selection-induced increases in the adhesion to ABO occurred in the absence of marked changes in immune IgG recognition of IE surface antigens, generally assumed to target mainly VSAs. Our study sheds new light on our understanding of the processes and molecules involved in IE sequestration and rosetting.
    [Show full text]
  • Structural Insight on the Recognition of Surface-Bound Opsonins by the Integrin I Domain of Complement Receptor 3
    Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3 Goran Bajica, Laure Yatimea, Robert B. Simb, Thomas Vorup-Jensenc,1, and Gregers R. Andersena,1 Departments of aMolecular Biology and Genetics and cBiomedicine, Aarhus University, DK-8000 Aarhus, Denmark; and bDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, United Kingdom Edited by Douglas T. Fearon, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, and approved August 28, 2013 (received for review June 13, 2013) Complement receptors (CRs), expressed notably on myeloid and degranulation, and changes in leukocyte cytokine production (2, lymphoid cells, play an essential function in the elimination of 5–7). CR3, and to a lesser degree CR4, are essential for the complement-opsonized pathogens and apoptotic/necrotic cells. In phagocytosis of complement-opsonized particles or complexes addition, these receptors are crucial for the cross-talk between the (6, 8, 9). Complement-opsonized immune complexes are cap- innate andadaptive branches ofthe immune system. CR3 (also known tured in the lymph nodes by CR3-positive subcapsular sinus as Mac-1, integrin α β , or CD11b/CD18) is expressed on all macro- macrophages (SSMs) and conveyed directly to naïve B cells or M 2 γ phages and recognizes iC3b on complement-opsonized objects, en- through follicular dendritic cells (10) using CR1, CR2, and Fc abling their phagocytosis. We demonstrate that the C3d moiety of receptors for antigen capture (11, 12). Hence, antigen-presenting iC3b harbors the binding site for the CR3 αI domain, and our structure cells such as SSMs may act as antigen storage and provide B of the C3d:αI domain complex rationalizes the CR3 selectivity for iC3b.
    [Show full text]
  • Complement Receptor 1 Therapeutics for Prevention of Immune Hemolysis
    Review: complement receptor 1 therapeutics for prevention of immune hemolysis K.YAZDANBAKHSH The complement system plays a crucial role in fighting infections biological activities, it has to be activated. Activation and is an important link between the innate and adaptive immune occurs in a sequence that involves proteolytic cleavage responses. However, inappropriate complement activation can cause tissue damage, and it underlies the pathology of many of the complement components, resulting in the diseases. In the transfusion medicine setting, complement release of active biological mediators and the assembly sensitization of RBCs can lead to both intravascular and of active enzyme molecules that result in cleavage of extravascular destruction. Moreover, complement deficiencies are 1 associated with autoimmune disorders, including autoimmune the next downstream complement component. hemolytic anemia (AIHA). Complement receptor 1 (CR1) is a large Depending on the nature of the activators, three single-pass glycoprotein that is expressed on a variety of cell types complement activation pathways have been described: in blood, including RBCs and immune cells. Among its multiple the antibody-dependent classical pathway and the functions is its ability to inhibit complement activation. Furthermore, gene knockout studies in mice implicate a role for antibody-independent alternative and lectin pathways CR1 (along with the alternatively spliced gene product CR2) in (Fig. 1).1 Common to all three pathways are two prevention of autoimmunity. This review discusses the possibility critical steps: the assembly of the C3 convertase that the CR1 protein may be manipulated to prevent and treat AIHA. In addition, it will be shown in an in vivo mouse model of enzymes and the activation of C5 convertases.
    [Show full text]
  • Microglia Receptors and Their Implications in the Response to Amyloid Β for Alzheimer’S Disease Pathogenesis Deborah Doens1,2 and Patricia L Fernández1*
    Doens and Fernández Journal of Neuroinflammation 2014, 11:48 JOURNAL OF http://www.jneuroinflammation.com/content/11/1/48 NEUROINFLAMMATION REVIEW Open Access Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis Deborah Doens1,2 and Patricia L Fernández1* Abstract Alzheimer’s disease (AD) is a major public health problem with substantial economic and social impacts around the world. The hallmarks of AD pathogenesis include deposition of amyloid β (Aβ), neurofibrillary tangles, and neuroinflammation. For many years, research has been focused on Aβ accumulation in senile plaques, as these aggregations were perceived as the main cause of the neurodegeneration found in AD. However, increasing evidence suggests that inflammation also plays a critical role in the pathogenesis of AD. Microglia cells are the resident macrophages of the brain and act as the first line of defense in the central nervous system. In AD, microglia play a dual role in disease progression, being essential for clearing Aβ deposits and releasing cytotoxic mediators. Aβ activates microglia through a variety of innate immune receptors expressed on these cells. The mechanisms through which amyloid deposits provoke an inflammatory response are not fully understood, but it is believed that these receptors cooperate in the recognition, internalization, and clearance of Aβ and in cell activation. In this review, we discuss the role of several receptors expressed on microglia in Aβ recognition, uptake, and signaling, and their implications for AD pathogenesis. Keywords: Cytokines, Inflammation, Microglia, Receptor Background Microglia constitute the lesser portion of the total glial Alzheimer’s disease (AD) is a neurodegenerative disorder cell population within the brain and are found in a rest- characterized by a progressive decline in cognitive and ing state in the healthy central nervous system (CNS) functional abilities.
    [Show full text]
  • A Role for CD36 in the Regulation of Dendritic Cell Function
    A role for CD36 in the regulation of dendritic cell function Britta C. Urban*†, Nick Willcox*, and David J. Roberts‡ *Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; and ‡National Blood Service, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom Edited by Philippa Marrack, National Jewish Medical and Research Center, Denver, CO, and approved May 14, 2001 (received for review January 18, 2001) Dendritic cells (DC) are crucial for the induction of immune responses peated infections despite large amounts of circulating antigen and thus an inviting target for modulation by pathogens. We have during the acute phases of the disease (11, 12). P. falciparum- previously shown that Plasmodium falciparum-infected erythrocytes infected erythrocytes (iRBC) express a clonally variant protein inhibit the maturation of DCs. Intact P. falciparum-infected erythro- (PfEMP-1) in the erythrocyte membrane that mediates binding cytes can bind directly to CD36 and indirectly to CD51. It is striking that to host cells (reviewed in ref. 13). Almost all variants of PfEMP1 these receptors, at least in part, also mediate the phagocytosis of analyzed so far bind to CD36 and͞or thrombospondin (TSP), apoptotic cells. Here we show that antibodies against CD36 or CD51, and individual variants may bind additionally to a variety of other as well as exposure to early apoptotic cells, profoundly modulate DC host receptors such as CD31 [platelet-endothelial cell adhesion maturation and function in response to inflammatory signals. Al- molecule (PECAM-1)], CD35 (complement receptor 1), CD51 ␣ ␣ though modulated DCs still secrete tumor necrosis factor- , they fail ( v integrin chain), or CD54 [intercellular adhesion molecule-1 to activate T cells and now secrete IL-10.
    [Show full text]
  • Role of Decay-Accelerating Factor in Regulating Complement Activation on the Erythrocyte Surface As Revealed by Gene Targeting
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 628–633, January 1999 Immunology Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting XIUJUN SUN*, COLIN D. FUNK*, CHENGJUN DENG*, ARVIND SAHU†,JOHN D. LAMBRIS†, AND WEN-CHAO SONG*‡ *Center for Experimental Therapeutics and Department of Pharmacology and †Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Edited by Stuart H. Orkin, Harvard Medical School, Boston, MA, and approved December 1, 1998 (received for review July 29, 1998) ABSTRACT Decay-accelerating factor (DAF) is a glyco- paroxysmal nocturnal hemoglobinuria (PNH) syndrome, a sylphosphatidylinositol (GPI)-anchored membrane protein disease characterized by an increased sensitivity of red blood that inhibits both the classical and the alternative pathways of cells to autologous complement-mediated lysis (7, 8). It is now complement activation. DAF has been studied extensively in understood that the fundamental defect in PNH occurs at the humans under two clinical settings: when absent from the stage of GPI anchor biosynthesis as a result of somatic erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) mutations in the PIG-A gene in hematopoietic stem cells rather patients, who suffer from complement-mediated hemolytic than a defect in the DAF gene per se (9). Thus, DAF and all anemia, and in transgenic pigs expressing human DAF, which other GPI-anchored proteins are absent from the affected have been developed to help overcome complement-mediated blood cells of PNH patients (9). hyperacute rejection in xenotransplantation. Nevertheless, The in vivo function of DAF in regulating complement the exact role of DAF in regulating complement activation in activation on the cell surface, highlighted by its absence from vivo on the cell surface and the species specificity of this the affected erythrocytes of PNH patients, remains an unset- molecule remain to be fully characterized.
    [Show full text]
  • The Impact of Complement Genes on the Risk of Late-Onset Alzheimer's
    G C A T T A C G G C A T genes Article The Impact of Complement Genes on the Risk of Late-Onset Alzheimer’s Disease Sarah M. Carpanini 1,2,† , Janet C. Harwood 3,† , Emily Baker 1, Megan Torvell 1,2, The GERAD1 Consortium ‡, Rebecca Sims 3 , Julie Williams 1 and B. Paul Morgan 1,2,* 1 UK Dementia Research Institute at Cardiff University, School of Medicine, Cardiff, CF24 4HQ, UK; [email protected] (S.M.C.); [email protected] (E.B.); [email protected] (M.T.); [email protected] (J.W.) 2 Division of Infection and Immunity, School of Medicine, Systems Immunity Research Institute, Cardiff University, Cardiff, CF14 4XN, UK 3 Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK; [email protected] (J.C.H.); [email protected] (R.S.) * Correspondence: [email protected] † These authors contributed equally to this work. ‡ Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium. As such, the investigators within the GERAD1 consortia contributed to the design and implementation of GERAD1 and/or provided data but did not participate in analysis or writing of this report. A full list of GERAD1 investigators and their affiliations is included in Supplementary File S1. Abstract: Late-onset Alzheimer’s disease (LOAD), the most common cause of dementia, and a huge global health challenge, is a neurodegenerative disease of uncertain aetiology. To deliver Citation: Carpanini, S.M.; Harwood, effective diagnostics and therapeutics, understanding the molecular basis of the disease is essential.
    [Show full text]
  • Complement Receptor 1 Gene Polymorphisms in Tunisian Patients with Systemic Lupus Erythematosus
    Journal of Medical Genetics and Genomics Vol. 1(1), pp. 001-007, October, 2009 Available online at http://www.academicjournals.org/JMGG © 2009 Academic Journals Full Length Research Paper Complement receptor 1 gene polymorphisms in Tunisian patients with systemic lupus erythematosus Imen Sfar1*, Yousr Gorgi1, Tarak Dhaouadi1, Lamia Ben Hassine2, Houda Aouadi1, Mouna Maklouf1, Thouraya Ben Romdhane1, Saloua Jendoubi-Ayed1, Narjess Khalfallah2, Adel Kheder3, Taieb Ben Abdallah1 and Khaled Ayed1 1Immunology research laboratory of kidney transplantation and immunopathology (Laboratoire de recherche LR03SP01). Charles Nicolle Hospital. Tunisia. 2Departments of Medicine. Charles Nicolle Hospital. Tunisia. 3Departments of Nephrology and Medicine. Charles Nicolle Hospital. Tunisia. Accepted 7 August, 2009 Complement receptor 1 (CR1) is a membrane protein mediating the transport of immune complexes (ICs) to phagocytes, and at least two polymorphisms on the CR1 gene are related to erythrocyte surface density of CR1 molecules, in turn related to the rate of IC clearance from circulation. The aim of the study was to explore whether the polymorphic sites of CR1 gene in exon 22 (His 1208 Arg), and exon 33 (Pro 1827 Arg), leading to amino acid change in the protein sequence are associated with systemic lupus erythematosus (SLE) susceptibility. To investigate this association, genomic DNA of 62 SLE patients and 76 healthy blood donors were genotyped by PCR-RFLP and direct sequencing. The CR1 analysis showed no significant association of the CR1 functional polymorphisms with SLE. However, the C/G genotype in Pro 1827 Arg polymorphism was significantly associated to nephritis and to the presence of cryoglobulins/ ICs compared to C/C and G/G genotypes (OR: 3.68, 95% confidence interval [CI], 1.028 - 13.2; p = 0.038 and OR: 16.6, 95% confidence interval [CI], 3.92 - 31.1; p=0.0002, respectively).
    [Show full text]
  • Complement in Tumourigenesis and the Response to Cancer Therapy
    cancers Review Complement in Tumourigenesis and the Response to Cancer Therapy Rebecca M. O’Brien 1,2, Aoife Cannon 1, John V. Reynolds 1, Joanne Lysaght 1,2 and Niamh Lynam-Lennon 1,* 1 Department of Surgery, Trinity St. James’s Cancer Institute, Trinity Translational Medicine Institute, Trinity College Dublin and St. James’s Hospital, Dublin 8, Ireland; [email protected] (R.M.O.); [email protected] (A.C.); [email protected] (J.V.R.); [email protected] (J.L.) 2 Cancer Immunology and Immunotherapy Group, Trinity St. James’s Cancer Institute, Trinity Translational Medicine Institute, Trinity College Dublin and St. James’s Hospital, Dublin 8, Ireland * Correspondence: [email protected] Simple Summary: Increasing evidence supports a role for complement in the development of cancer and the response to cancer treatments. Dysregulated complement expression within the tumour microenvironment has been linked to the suppression of anti-tumour immunity and poor clinical outcomes. Complement signals have been demonstrated to alter the immune milieu, promote proliferation and facilitate metastasis. Targeting complement signalling in combination with current treatments may have the potential to achieve improved control of tumour growth. Abstract: In recent years, our knowledge of the complement system beyond innate immunity has progressed significantly. A modern understanding is that the complement system has a multifaceted role in malignancy, impacting carcinogenesis, the acquisition of a metastatic phenotype and response to therapies. The ability of local immune cells to produce and respond to complement components has provided valuable insights into their regulation, and the subsequent remodeling of the tumour Citation: O’Brien, R.M.; Cannon, A.; Reynolds, J.V.; Lysaght, J.; microenvironment.
    [Show full text]